aldosterone antagonists

Summary

Summary: Compounds which inhibit or antagonize the biosynthesis or actions of aldosterone.

Top Publications

  1. ncbi Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
    Bertram Pitt
    University of Michigan, Ann Arbor, USA
    N Engl J Med 348:1309-21. 2003
  2. ncbi Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
    David N Juurlink
    Department of Medicine University of Toronto, Toronto
    N Engl J Med 351:543-51. 2004
  3. doi Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors
    Matthew R Weir
    Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, 22 South Greene Street, Room N3W143, Baltimore, MD 21201, USA
    Clin J Am Soc Nephrol 5:531-48. 2010
  4. pmc Aldosterone-induced inflammation in the rat heart : role of oxidative stress
    Yao Sun
    Department of Medicine, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis 38163, USA
    Am J Pathol 161:1773-81. 2002
  5. doi Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis
    Puneeta Tandon
    Hospital Clinic, Liver Unit, Barcelona, Spain
    J Hepatol 53:273-82. 2010
  6. doi Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol
    Ingrid J M Duijkers
    Dinox, Groningen, The Netherlands
    Eur J Contracept Reprod Health Care 15:314-25. 2010
  7. doi Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker
    Yoshiyuki Furumatsu
    Department of Kidney Disease and Hypertension, Osaka General Medical Center, Japan
    Hypertens Res 31:59-67. 2008
  8. ncbi Cardiac aldosterone production in genetically hypertensive rats
    Y Takeda
    Second Department of Internal Medicine, Department of Health Sciences, School of Medicine, Kanazawa University, Kanazawa, Japan
    Hypertension 36:495-500. 2000
  9. doi Eplerenone in patients with systolic heart failure and mild symptoms
    Faiez Zannad
    INSERM, Centre d Investigation Clinique 9501 and Unité 961, and the Department of Cardiology, Nancy University, Nancy, France
    N Engl J Med 364:11-21. 2011
  10. pmc Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity
    Jane A Leopold
    Whitaker Cardiovascular Institute, 700 Albany Street, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Nat Med 13:189-97. 2007

Detail Information

Publications220 found, 100 shown here

  1. ncbi Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
    Bertram Pitt
    University of Michigan, Ann Arbor, USA
    N Engl J Med 348:1309-21. 2003
    ....
  2. ncbi Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
    David N Juurlink
    Department of Medicine University of Toronto, Toronto
    N Engl J Med 351:543-51. 2004
    ..Use of angiotensin-converting-enzyme (ACE) inhibitors is also indicated in these patients. However, life-threatening hyperkalemia can occur when these drugs are used together...
  3. doi Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors
    Matthew R Weir
    Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, 22 South Greene Street, Room N3W143, Baltimore, MD 21201, USA
    Clin J Am Soc Nephrol 5:531-48. 2010
    ..Moreover, these patients are likely to derive benefit from RAAS inhibition. Rather than denying them an effective treatment, electrolyte levels should be closely monitored in these patients...
  4. pmc Aldosterone-induced inflammation in the rat heart : role of oxidative stress
    Yao Sun
    Department of Medicine, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis 38163, USA
    Am J Pathol 161:1773-81. 2002
    ..Spionolactone, PDTC, and NAC each attenuated these responses suggesting ALDO/salt induction of oxidative/nitrosative stress is responsible for the appearance of this proinflammatory phenotype...
  5. doi Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis
    Puneeta Tandon
    Hospital Clinic, Liver Unit, Barcelona, Spain
    J Hepatol 53:273-82. 2010
    Renin-angiotensin-aldosterone antagonists [ACE inhibitors (ACEi), angiotensin receptor blockers (ARB), aldosterone antagonists (AA)] are potential therapies for portal hypertension...
  6. doi Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol
    Ingrid J M Duijkers
    Dinox, Groningen, The Netherlands
    Eur J Contracept Reprod Health Care 15:314-25. 2010
    ..To compare the effects on ovarian activity of two oral contraceptives containing nomegestrol acetate (NOMAC)/17 beta-oestradiol (E2) or drospirenone (DRSP)/ethinylestradiol (EE)...
  7. doi Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker
    Yoshiyuki Furumatsu
    Department of Kidney Disease and Hypertension, Osaka General Medical Center, Japan
    Hypertens Res 31:59-67. 2008
    ..In conclusion, triple blockade of the RAAS was effective for the treatment of proteinuria in patients with non-diabetic nephropathy whose increased urinary protein had not responded sufficiently to a dual blockade...
  8. ncbi Cardiac aldosterone production in genetically hypertensive rats
    Y Takeda
    Second Department of Internal Medicine, Department of Health Sciences, School of Medicine, Kanazawa University, Kanazawa, Japan
    Hypertension 36:495-500. 2000
    ..These results suggest that the rat heart produces aldosterone and that endogenous cardiac aldosterone may affect cardiac function and hypertrophy in hypertension in rats...
  9. doi Eplerenone in patients with systolic heart failure and mild symptoms
    Faiez Zannad
    INSERM, Centre d Investigation Clinique 9501 and Unité 961, and the Department of Cardiology, Nancy University, Nancy, France
    N Engl J Med 364:11-21. 2011
    ..We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms...
  10. pmc Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity
    Jane A Leopold
    Whitaker Cardiovascular Institute, 700 Albany Street, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Nat Med 13:189-97. 2007
    ..These findings demonstrate that aldosterone induces a G6PD-deficient phenotype to impair endothelial function; aldosterone antagonism or gene transfer of G6pd improves vascular reactivity by restoring G6PD activity...
  11. ncbi Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1
    Shigeru Shibata
    Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Hypertension 49:355-64. 2007
    ..Aldosterone can directly modulate podocyte function, possibly through the induction of oxidative stress and Sgk1...
  12. doi Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology
    Jennifer L Wilkinson-Berka
    Department of Immunology, Monash University, Commercial Rd, Prahran, Victoria, Australia, 3004
    Circ Res 104:124-33. 2009
    ..We make the first report that MR and aldosterone influence retinal vasculopathy, which may involve inflammatory and G6PD mechanisms. MR antagonism may be relevant when developing treatments for retinopathies that target the RAAS...
  13. ncbi Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
    N J Brown
    Departments of Medicine and Pharmacology, Pathology, and Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Kidney Int 58:1219-27. 2000
    ....
  14. doi Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet
    Tsutomu Wada
    Department of Clinical Pharmacology, University of Toyama, Toyama 930 0194, Japan
    Endocrinology 151:2040-9. 2010
    ..These results indicate that inhibition of mineralocorticoid receptor might be a beneficial therapeutic approach for diet-induced phenotypes of metabolic syndrome and fatty liver...
  15. ncbi Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes
    Murray Epstein
    University of Miami School of Medicine, Miami, Florida, USA
    Clin J Am Soc Nephrol 1:940-51. 2006
    ..Co-administration of EPL50 or EPL100 with an ACE inhibitor as compared with an ACE inhibitor alone significantly reduces albuminuria in patients with diabetes without producing significant increases in hyperkalemia...
  16. pmc Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt
    William B Lea
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Kidney Int 75:936-44. 2009
    ..Our study shows that mineralocorticoid receptor antagonism and aldosterone synthase inhibition similarly decrease hypertrophy and interstitial fibrosis of the kidney and heart caused by angiotensin II and high salt...
  17. ncbi Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis
    Morag Young
    Endocrine Genetics, Prince Henry s Institute of Medical Research, Clayton, Victoria 3168, Australia
    Endocrinology 144:3848-51. 2003
    ....
  18. ncbi Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats
    Genro Fujisawa
    Divisions of Endocrinology, Department of Internal Medicine, Jichi Medical School, Minamikawachi, Tochigi, Japan
    Kidney Int 66:1493-502. 2004
    ..The present study investigated whether and how mineralocorticoid receptor antagonist spironolactone ameliorates early renal injury in streptozotocin-induced diabetic rats...
  19. ncbi Use of aldosterone antagonists in heart failure
    Nancy M Albert
    Nursing Institute and Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio, USA
    JAMA 302:1658-65. 2009
    b>Aldosterone antagonists are recommended for patients with moderate to severe heart failure (HF) and systolic dysfunction...
  20. ncbi Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker
    Miki Nagase
    Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
    Hypertension 47:1084-93. 2006
    ....
  21. doi Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats
    Jun Du
    Department of Pharmacology, Kagawa University Medical School, Kagawa, Japan
    Am J Physiol Renal Physiol 297:F802-8. 2009
    ..The combination of eplerenone and amlodipine improved renal injury more effectively than either monotherapy in high salt-fed DS rats, presumably by achieving their own renoprotective effects...
  22. ncbi Effects of eplerenone versus losartan in patients with low-renin hypertension
    Myron H Weinberger
    Hypertension Research Center, Indiana University School of Medicine, Indianapolis, IN 46202 5111, USA
    Am Heart J 150:426-33. 2005
    ..Agents that block aldosterone at its receptor sites, therefore, should have significant clinical benefit in patients with low-renin hypertension...
  23. ncbi Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines
    Biykem Bozkurt
    Winters Center for Heart Failure Research, VA Medical Center, Baylor College of Medicine, Houston, Texas, USA
    J Am Coll Cardiol 41:211-4. 2003
    ..This study was designed to investigate the appropriateness and complications of the use of spironolactone for heart failure (HF) in clinical practice...
  24. doi Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials
    Justin A Ezekowitz
    Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada
    Eur Heart J 30:469-77. 2009
    ..Aldosterone blockade has been used to treat acute myocardial infarction (MI) and chronic heart failure...
  25. doi A comparison of the aldosterone-blocking agents eplerenone and spironolactone
    Allan Struthers
    Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee, UK
    Clin Cardiol 31:153-8. 2008
    ..Choice of a specific agent should be based on individual patient issues, such as the nature of heart failure and patient concerns about adverse events...
  26. ncbi Mineralocorticoid receptor antagonism in experimental atherosclerosis
    Sanjay Rajagopalan
    Department of Internal Medicine, University of Michigan, Ann Arbor, Mich, USA srajagop umich edu
    Circulation 105:2212-6. 2002
    ..We hypothesized that there is local expression of the mineralocorticoid receptor (MR) in the vasculature and that the use of a selective aldosterone receptor antagonist (SARA) improves endothelial function in early atherosclerosis...
  27. ncbi Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study
    Bertram Pitt
    University of Michigan Health System, Ann Arbor, Mich, USA
    Circulation 108:1831-8. 2003
    ..This study compared LVH regression during treatment with the selective aldosterone blocker eplerenone, enalapril, and their combination in patients with hypertension...
  28. ncbi Long-term renal outcomes in patients with primary aldosteronism
    Leonardo A Sechi
    Hypertension Unit, Division of Internal Medicine, Department of Experimental and Clinical Pathology and Medicine, University of Udine, Udine, Italy
    JAMA 295:2638-45. 2006
    ..Experimental animal studies indicate that exposure to increased aldosterone levels might result in renal damage, but the clinical evidence supporting this role of aldosterone is preliminary...
  29. ncbi Low-dose spironolactone in the management of resistant hypertension: a surveillance study
    Deirdre A Lane
    University Department of Medicine, City Hospital, Birmingham, UK
    J Hypertens 25:891-4. 2007
    ..This drug was recommended in 133 patients who were already receiving an angiotensin-blocking drug in addition to other therapies...
  30. ncbi Induction of cardiac fibrosis by aldosterone
    P Lijnen
    Department of Molecular and Cardiovascular Research, Faculty of Medicine, University of Leuven, Belgium
    J Mol Cell Cardiol 32:865-79. 2000
    ....
  31. ncbi Aldosterone antagonist improves diastolic function in essential hypertension
    Anna M Grandi
    Department of Clinical and Biological Sciences, University of Insubria, Varese, Italy
    Hypertension 40:647-52. 2002
    ..This improvement, not accounted for by changes in blood pressure and left ventricular mass, can be therefore ascribed to a direct action of the drug on the myocardium...
  32. ncbi Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition
    Christian Otte
    Department of Psychiatry and Psychotherapy, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Neuropsychopharmacology 32:232-8. 2007
    ..The domains of cognitive function that are impaired after blockade of MR in men, that is, selective attention, visuospatial memory, and mental flexibility/set shifting appear to be remarkably similar to those described in animal studies...
  33. ncbi Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease
    Atsuhisa Sato
    Department of Internal Medicine, Mito Red Cross Hospital, Ibaraki, Japan
    Am J Hypertens 18:44-9. 2005
    ..Additional, larger, prospective, randomized double-blind studies will be needed for general acceptance of this strategy...
  34. ncbi Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats
    Genro Fujisawa
    Divisions of Endocrinology and Metabolism and Nephrology, Department of Internal Medicine, Jichi Medical School, Minamikawachi, Tochigi, Japan
    Transl Res 148:149-56. 2006
    ..The aldosterone produced in the injured liver contributes to the PS-induced hepatic fibrosis...
  35. pmc Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy
    Uzma F Mehdi
    University of Texas Southwestern Medical Center, 5939 Harry Hines Boulevard, Dallas, TX 75930, USA
    J Am Soc Nephrol 20:2641-50. 2009
    ..These results support the need to conduct a long-term, large-scale, renal failure outcomes trial...
  36. ncbi Aldosterone target organ protection by eplerenone
    Amy E Rudolph
    Pharmacia Corporation, Cardiovascular and Metabolic Diseases, 800 N Lindbergh Blvd, T1G T108W, St Louis, MO 63167, USA
    Mol Cell Endocrinol 217:229-38. 2004
    ....
  37. ncbi Beneficial impact of spironolactone in diabetic nephropathy
    Katrine Jordan Schjoedt
    Steno Diabetes Center, Gentofte, Denmark
    Kidney Int 68:2829-36. 2005
    ..We therefore aimed to evaluate the short-term effect of aldosterone antagonism with spironolactone on albuminuria and blood pressure in diabetic nephropathy...
  38. doi Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats
    Bing S Huang
    University of Ottawa Heart Institute, Ottawa, ON, Canada K1Y 4W7
    Am J Physiol Regul Integr Comp Physiol 296:R994-R1000. 2009
    ..These results suggest that, in Dahl S rats, high salt intake increases aldosterone synthesis in the hypothalamus and aldosterone acts as the main MR agonist activating central pathways contributing to salt-induced hypertension...
  39. doi Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure
    Larisa H Cavallari
    Department of Pharmacy Practice, University of Illinois at Chicago, 60612 7230, USA
    Pharmacotherapy 30:1-9. 2010
    ..To identify patient-specific factors associated with spironolactone-induced potassium level elevation in patients with heart failure...
  40. ncbi Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction
    James E Udelson
    Tufts Medical Center, 750 Washington Street, Boston, MA 02111, USA
    Circ Heart Fail 3:347-53. 2010
    ..Few data are available on effects of aldosterone antagonism in patients with mild-to-moderate HF...
  41. ncbi Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF)
    Faiez Zannad
    INSERM, Centre d Investigation Cliniques CIC 9501 and U961, CHU and Department of Cardiology, Nancy University, Nancy, France
    Eur J Heart Fail 12:617-22. 2010
    In chronic heart failure (HF), aldosterone antagonists have been shown to improve survival in patients with low ejection fraction and moderate-to-severe symptoms [New York Heart Association (NYHA) classes III and IV]...
  42. ncbi Spironolactone improves diastolic function in the elderly
    Chanwit Roongsritong
    Division of Cardiology, Texas Tech University Health Sciences Center, Lubbock, TX 79430 9410, USA
    Clin Cardiol 28:484-7. 2005
    ..Increased myocardial fibrosis, a major determinant of diastolic function, has been observed with advancing age. Spironolactone prevents age-related increases in myocardial fibrosis in old normotensive rats...
  43. ncbi Long-term effect of spironolactone on cardiac structure as assessed by analysis of ultrasonic radio-frequency signals in patients with ventricular hypertrophy
    Nagahiro Nishikawa
    Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita 565 0871, Japan
    Circ J 69:1394-400. 2005
    ....
  44. ncbi Spironolactone use and renal toxicity: population based longitudinal analysis
    Li Wei
    Medicines Monitoring Unit MEMO, Division of Medical Sciences, Ninewells Hospital and Medical School, Dundee DD1 9SY
    BMJ 340:c1768. 2010
    ..To determine the safety of spironolactone prescribing in the setting of the UK National Health Service...
  45. ncbi Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study
    Jürgen Dinger
    Director, ZEG Berlin Center for Epidemiology and Health Research, Invalidenstrasse 115, 10115 Berlin, Germany
    J Fam Plann Reprod Health Care 36:123-9. 2010
    ..The secondary objective was to investigate the VTE risk associated with drospirenone/ethinylestradiol (DRSP/EE) in comparison to low-dose LNG/EE...
  46. pmc Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion
    Massimiliano Caprio
    Department of Medicine Division of Cardiology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
    Circ Res 102:1359-67. 2008
    In clinical trials, aldosterone antagonists decrease cardiovascular mortality and ischemia by unknown mechanisms...
  47. doi Safety of spironolactone use in ambulatory heart failure patients
    Ricardo J Lopes
    Department of Cardiology, Hospital São João 4200 319 Porto, Portugal
    Clin Cardiol 31:509-13. 2008
    ..There is limited information on the use, side effects, and withdrawal rate of spironolactone in routine clinical practice...
  48. doi Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease
    Richard A Preston
    Division of Clinical Pharmacology, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    Hypertension 53:754-60. 2009
    ....
  49. doi Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results
    Alessandro Boccanelli
    Department of Cardiovascular Diseases, San Giovanni Addolorata Hospital, Roma, Italy
    Eur J Heart Fail 11:68-76. 2009
    ..Aldosterone receptor antagonists improve outcome in severe HF, but no information is available in NYHA class II...
  50. ncbi The new biology of aldosterone
    John M C Connell
    MRC Blood Pressure Group, Division of Cardiovascular and Medical Sciences, University of Glasgow, Gardiner Institute, Western Infirmary, Glasgow G11 6NT, UK
    J Endocrinol 186:1-20. 2005
    ..These new findings highlight the role of aldosterone as a key cardiovascular hormone and extend our understanding of its role in determining adverse cardiovascular outcomes...
  51. ncbi Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study
    Stefano Bianchi
    Unità Operativa Nefrologica, Spedali Riuniti di Livorno, Livorno, Italy
    Am J Kidney Dis 46:45-51. 2005
    ..Hence, administration of aldosterone receptor antagonists may provide additional renal benefits to the ACE inhibitors and ARBs...
  52. doi Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone
    Paul Mulder
    Faculte de Medecine et Pharmacie, INSERM U644, 22 Boulevard Gambetta, 76183 Rouen Cedex, France
    Eur Heart J 29:2171-9. 2008
    ..Inhibition of aldosterone synthase, the key enzyme in aldosterone formation, could be an alternative strategy for mineralocorticoid-receptor antagonists in congestive heart failure (CHF), but its effect in CHF is unknown...
  53. ncbi Review of aldosterone- and angiotensin II-induced target organ damage and prevention
    Allan D Struthers
    Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Tayside DD1 9SY, Dundee, UK
    Cardiovasc Res 61:663-70. 2004
    ....
  54. pmc Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis
    Sankar D Navaneethan
    Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Clin J Am Soc Nephrol 4:542-51. 2009
    Addition of aldosterone antagonists (AA) might provide renal benefits to proteinuric chronic kidney disease (CKD) patients over and above the inhibition of renin-angiotensin system blockers (RAS)...
  55. ncbi The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation
    Jürgen C Dinger
    Center for Epidemiology and Health Research ZEG, 10115 Berlin, Germany
    Contraception 75:344-54. 2007
    ..The study was conducted to compare risks of adverse cardiovascular and other events associated with the use of drospirenone (DRSP)-containing oral contraceptives (OCs) and other OCs...
  56. doi Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)
    Bertram Pitt
    University of Michigan Medical Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109, USA
    Circulation 118:1643-50. 2008
    ..This subanalysis examined the relationship between eplerenone, serum potassium (K(+)), and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)...
  57. ncbi Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction
    Carmem Luíza Sartório
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Wurzburg, Bayerische Julius Maximilians Universität Würzburg, Germany
    Hypertension 50:919-25. 2007
    ..Underlying mechanisms involve inhibition of vascular angiotensin-converting enzyme upregulation and improvement of endothelial NO synthase-derived NO bioavailability...
  58. ncbi Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial
    Leszek Tylicki
    Department of Nephrology Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland
    Am J Kidney Dis 52:486-93. 2008
    ....
  59. ncbi Rapid non-genomic vasoconstrictor actions of aldosterone in the renal microcirculation
    Shuji Arima
    Department of Vascular and Geriatric Medicine, Kinki University School of Medicine, 377 2 Ohno Higashi, Osaka Sayama 589 8511, Japan
    J Steroid Biochem Mol Biol 102:170-4. 2006
    ..Thus, in addition to genomic actions, such non-genomic vasoconstrictor actions in the renal microcirculation may contribute to the deleterious renal effects of aldosterone in renal diseases...
  60. ncbi Effect of spironolactone on blood pressure in subjects with resistant hypertension
    Neil Chapman
    International Centre for Circulatory Health, Imperial College London, 59 North Wharf Rd, London W2 1PG, United Kingdom
    Hypertension 49:839-45. 2007
    ..Although nonrandomized and not placebo controlled, these data support the use of spironolactone in uncontrolled hypertension...
  61. ncbi Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome
    Robert W Schrier
    Department of Medicine, University of Colorado Denver, Division of Renal Diseases and Hypertension, Aurora, CO 80045, USA
    Clin J Am Soc Nephrol 5:1132-40. 2010
    ..The effect of aldosterone in metabolic syndrome is also discussed in this review...
  62. ncbi Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes
    E Harada
    Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Japan
    Circulation 104:137-9. 2001
    ..Thus, spironolactone may suppress the progression of heart failure by blocking the effects of aldosterone and angiotensin II...
  63. ncbi Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship
    F Zannad
    Centre d'Investigation Clinique INSERM-CHU, Centre Hospitalier Universitaire, Equipe d'Accueil EA 2403, , Nancy, France
    Hypertension 38:1227-32. 2001
    ....
  64. ncbi Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage
    Anette Fiebeler
    Medical Faculty of the Charite, HELIOS Klinikum Berlin, Franz Volhard Clinic, Berlin, Germany
    Circulation 111:3087-94. 2005
    ..We tested the hypothesis that reducing aldosterone by inhibiting CYP11B2 or by adrenalectomy (ADX) may ameliorate organ damage. Furthermore, we investigated how much local cardiac aldosterone originates from the adrenal gland...
  65. doi Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism
    Rosana Poggio
    Heart Failure and Heart Transplant Program, Department of Cardiology, FLENI, Buenos Aires, Argentina
    Postgrad Med J 86:136-42. 2010
    ..of angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and aldosterone antagonists. High potassium concentrations in heart failure could lead to life threatening events, and therefore ..
  66. ncbi Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability
    Toshio Imanishi
    Department of Cardiovascular Medicine, Wakayama Medical University, 811 1, Kimiidera, Wakayama City, Wakayama 641 8510, Japan
    Hypertension 51:734-41. 2008
    ..Combined treatment with a selective aldosterone antagonist and an angiotensin-converting enzyme inhibitor has additive protective effects on endothelial function and on atherosclerotic changes via decreased nitrosative stress...
  67. ncbi Pharmacology of different progestogens: the special case of drospirenone
    R Sitruk-Ware
    Rockefeller University and Population Council, New York, NY 10021, USA
    Climacteric 8:4-12. 2005
    ..Drospirenone is also available in combination with estradiol as an HRT preparation (1 mg 17beta-estradiol/2 mg drospirenone; Angeliq, Schering AG)...
  68. ncbi Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II
    Anastasia Chrysostomou
    Department of Nephrology, Royal Melbourne Hospital, Parkville, Victoria 3052, Australia
    Clin J Am Soc Nephrol 1:256-62. 2006
    ..Results suggest no advantage of triple blockade over dual blockade of the renin-angiotensin-aldosterone system to reduce proteinuria...
  69. ncbi Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001
    Frederick A Masoudi
    Division of Cardiology, Department of Medicine, Denver Health Medical Center, Denver, CO 80204, USA
    Circulation 112:39-47. 2005
    ..We studied the adoption of spironolactone therapy after publication of the Randomized Aldactone Evaluation Study (RALES) in national cohorts of older patients hospitalized for heart failure...
  70. pmc Mineralocorticoid receptor antagonists and endothelial function
    Bradley A Maron
    Harvard Medical School, Brigham and Women s Hospital, Department of Medicine, Cardiovascular Division, 77 Avenue Louis Pasteur, NRB 0630K, Boston, MA 02115, USA
    Curr Opin Investig Drugs 9:963-9. 2008
    ..Therefore, the development of newer agents with more favorable side-effect profiles is needed...
  71. ncbi Spironolactone improves angiotensin-induced vascular changes and oxidative stress
    Agostino Virdis
    Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Quebec, Canada
    Hypertension 40:504-10. 2002
    ..Our findings suggest that aldosterone may mediate some of angiotensin II-induced vascular effects in hypertension, in part via increased oxidative stress...
  72. ncbi Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
    Myron H Weinberger
    Indiana University School of Medicine, Hypertension Research Center, Indianapolis 46202 5111, USA
    Am J Hypertens 15:709-16. 2002
    ..Eplerenone, a selective aldosterone blocker (SAB) that is highly specific for the aldosterone receptor, has the potential to be efficacious in the treatment of hypertension...
  73. ncbi Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism
    Asterios Karagiannis
    Aristotle University of Thessaloniki, Second Propedeutic Department of Internal Medicine, Medical School, Hippokration Hospital, Thessaloniki, Greece
    Expert Opin Pharmacother 9:509-15. 2008
    ..It was concluded that eplerenone was as effective as spironolactone in reducing BP in patients with IHA. The risk of mild hyperkalaemia was similar with both drugs...
  74. ncbi Rationale for the use of aldosterone antagonists in congestive heart failure
    Ricardo Rocha
    Division of Cardiovascular and Metabolic Diseases, Pharmacia Corp, Skokie, Illinois, USA
    Drugs 62:723-31. 2002
    ..These findings suggest the dissociation between cardiovascular lesions and high blood pressure, and highlight the importance of aldosterone in the pathological changes...
  75. ncbi Eplerenone: cardiovascular protection
    Nancy J Brown
    Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn 37232 6602, USA
    Circulation 107:2512-8. 2003
    ..This review provides an overview of the pharmacology, efficacy, and safety of a new, more selective aldosterone receptor antagonist, eplerenone, in the context of emerging concepts of the role of aldosterone in cardiovascular toxicity...
  76. ncbi Aldosterone antagonists in the treatment of heart failure
    Todd R Marcy
    University of Oklahoma College of Pharmacy, Oklahoma City, OK 73190, USA
    Am J Health Syst Pharm 63:49-58. 2006
    The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart failure are reviewed.
  77. ncbi High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction
    Farzin Beygui
    Cardiology Department and INSERM U 856, Pitie Salpetriere University Hospital, Paris, France
    Circulation 114:2604-10. 2006
    ..Whether aldosterone level at presentation for STEMI is associated with adverse outcome remains unknown...
  78. ncbi How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
    Morten Svensson
    Frederiksberg University Hospital, Department of Cardiology and Endocrinology Frederiksberg Copenhagen, Denmark
    J Card Fail 10:297-303. 2004
    ....
  79. ncbi A review of the medical treatment of primary aldosteronism
    P O Lim
    Department of Cardiology, Wales Heart Research Institute, University of Wales College of Medicine, Cardiff
    J Hypertens 19:353-61. 2001
    ..There is thus a timely need to review the literature for effective drug therapies and to speculate on other therapeutic options by taking into account recent advances in understanding of the PA disease pathophysiological process...
  80. ncbi Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension
    Krishna K Gaddam
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 115 Community Health Services Building, 933 19 Street South, Birmingham, AL 35294, USA
    Expert Rev Cardiovasc Ther 4:353-9. 2006
    ..Recent clinical studies indicate that aldosterone antagonists provide significant additional blood pressure reduction when added to treatment regimens of patients with ..
  81. ncbi Use of aldosterone antagonists in resistant hypertension
    David A Calhoun
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, USA
    Prog Cardiovasc Dis 48:387-96. 2006
    ..Recent clinical studies indicate that aldosterone antagonists, spironolactone and amiloride, provide significant additional blood pressure reduction when added to ..
  82. ncbi Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice
    John McMurray
    Department of Cardiology, Western Infirmary, Glasgow, G12 8QQ, UK
    Eur J Heart Fail 7:710-21. 2005
    ..Recent trials have now shown that treatment with beta-blockers, aldosterone antagonists and angiotensin receptor blockers also leads to substantial improvements in outcome...
  83. ncbi Drospirenone, a new progestogen, for postmenopausal women with hypertension
    Madhavi Mallareddy
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
    Drugs Aging 24:453-66. 2007
    ..Thus, drospirenone is a unique progestogen that confers the additional benefit of BP reduction, an effect that could lead to potential benefit with respect to some cardiovascular risk concerns in women taking hormone therapy...
  84. ncbi The role of aldosterone antagonists in the management of resistant hypertension
    Mari K Nishizaka
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 430 BMR2, 1530 3rd Avenue South, Birmingham, AL 35294 2180, USA
    Curr Hypertens Rep 7:343-7. 2005
    ..Recent studies indicate that aldosterone antagonists provide significant blood pressure reduction when added to antihypertensive regimens of patients with ..
  85. ncbi Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension
    William B White
    Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    Circulation 112:1979-84. 2005
    ..In prior studies with DRSP in postmenopausal women that were focused on relief of menopausal symptoms, DRSP/E2 yielded significant reductions in blood pressure (BP)...
  86. ncbi Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms
    O Ylikorkala
    Climacteric 8:1-3. 2005
  87. ncbi Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinas
    Shigefumi Nakano
    Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Shimotsuga gun, Tochigi 321 0293, Japan
    Hypertens Res 28:925-36. 2005
    ..Spironolactone may be useful as a cardioprotective agent to prevent cardiovascular remodeling via the ACE/EGFR/ERK, NAD(P)H oxidase/LOX-1, and Rho-kinase pathways...
  88. ncbi Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study
    B S Lee
    Department of Obstetrics and Gynecology, College of Medicine, Yonsei University, Seoul, Republic of Korea
    Maturitas 57:361-9. 2007
    ....
  89. ncbi Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study
    Hideo Izawa
    Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya 466 8550, Japan
    Circulation 112:2940-5. 2005
    ....
  90. ncbi Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease
    Richard N Re
    Research Division, Ochsner Clinic Foundation, New Orleans, LA 70121, USA
    Nat Clin Pract Cardiovasc Med 1:42-7. 2004
    ....
  91. ncbi Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial
    David F Archer
    CONRAD Clinical Research Center, 601 Colley Avenue, Norfolk, VA 23507, USA
    Menopause 12:716-27. 2005
    ....
  92. ncbi Drospirenone and its antialdosterone properties
    A R Genazzani
    Department of Obstetrics and Gynecology, University of Pisa, Pisa, Italy
    Climacteric 10:11-8. 2007
    ..The combined actions of drospirenone on sodium and water retention and cardiovascular parameters make it a more attractive therapeutic option as a component of hormone replacement therapy than other synthetic progestins...
  93. ncbi Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes
    Lorenzo A Calo
    Department of Clinical and Experimental Medicine, Clinica Medica 4, University of Padua, Padua 35100, Italy
    J Clin Endocrinol Metab 89:1973-6. 2004
    ..In addition, the results confirm our previous data on a direct effect of glycyrrhetinic acid at the level of mineralocorticoid receptors...
  94. ncbi Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation
    Hylton V Joffe
    Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women s Hospital, Harvard Medical School, 221 Longwood Ave, Boston, MA 02115, USA
    Heart Fail Rev 10:31-7. 2005
    ..This review focuses on the adverse effects of aldosterone on the vascular system and describes our current understanding of the underlying mechanisms for this injury...
  95. pmc Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats
    G Miric
    Department of Physiology and Pharmacology, School of Biomedical Sciences, The University of Queensland, Australia
    Br J Pharmacol 133:687-94. 2001
    ..Thus, short-term pirfenidone and spironolactone treatment reversed cardiac and renal fibrosis and attenuated the increased diastolic stiffness without normalizing cardiac contractility or renal function in STZ-diabetic rats...
  96. ncbi Aldosterone-induced vasculopathy
    Allan D Struthers
    Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK
    Mol Cell Endocrinol 217:239-41. 2004
    b>Aldosterone antagonists reduce mortality in chronic heart failure (CHF). An obvious question to ask is how do they do this...
  97. ncbi Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction
    Howard Trachtman
    Department of Pediatrics, Schneider Children s Hospital, New Hyde Park, New York 11040, USA
    J Urol 172:1590-4. 2004
    ..We conducted experiments to determine whether administration of spironolactone, a mineralocorticoid receptor antagonist, reduced renal fibrosis in an experimental model of obstructive uropathy...
  98. pmc Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment
    J E Macdonald
    Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee DD19SY, UK
    Heart 90:765-70. 2004
    ....
  99. ncbi Rapid effects of aldosterone on vascular cells: clinical implications
    Ralf Losel
    Department of Clinical Pharmacology Mannheim, Institut fur Klinische Pharmakologie, University of Heidelberg, Klinikum Mannheim, Theodor Kutzer Ufer, D 68167 Mannheim, Germany
    Steroids 69:575-8. 2004
    ..As many rapid and thus nonclassic aldosterone responses cannot be blocked by spironolactone, further research is required in order to provide adequate inhibitors to interfere with these pathways...
  100. ncbi Aldosterone blockade: an emerging strategy for abrogating progressive renal disease
    Murray Epstein
    Department of Medicine, University of Miami School of Medicine, Miami, Fla, USA
    Am J Med 119:912-9. 2006
    ....
  101. ncbi Hypertension, angiotensin II, aldosterone, and race
    Ori Ben-Yehuda
    J Am Coll Cardiol 41:1156-8. 2003

Research Grants123 found, 100 shown here

  1. Genetic determinants of aldosterone escape in heart failure
    Larisa Cavallari; Fiscal Year: 2009
    ..goal of this line of investigation is to determine whether genotype is predictive of response to aldosterone antagonists in heart failure...
  2. Etiology of Sleep Apnea-Related Hyperaldosteronism
    David Calhoun; Fiscal Year: 2008
    ..Both possibilities would significantly lower cardiovascular risk in patients with difficult-to-control hypertension. ..
  3. Etiology of Sleep Apnea-Related Hyperaldosteronism
    David Calhoun; Fiscal Year: 2004
    ..Subjects found not to have OSA will serve as controls. ..
  4. Etiology of Sleep Apnea-Related Hyperaldosteronism
    David A Calhoun; Fiscal Year: 2010
    ..Both possibilities would significantly lower cardiovascular risk in patients with difficult-to-control hypertension. ..
  5. Etiology of Sleep Apnea-Related Hyperaldosteronism
    David Calhoun; Fiscal Year: 2009
    ..Both possibilities would significantly lower cardiovascular risk in patients with difficult-to-control hypertension. ..
  6. Etiology of Sleep Apnea-Related Hyperaldosteronism
    David Calhoun; Fiscal Year: 2007
    ..Subjects found not to have OSA will serve as controls. [unreadable] [unreadable]..
  7. Etiology of Sleep Apnea-Related Hyperaldosteronism
    David Calhoun; Fiscal Year: 2005
    ..Subjects found not to have OSA will serve as controls. ..
  8. Etiology of Sleep Apnea-Related Hyperaldosteronism
    David Calhoun; Fiscal Year: 2006
    ..Subjects found not to have OSA will serve as controls. [unreadable] [unreadable]..
  9. Diabetes and Drug-Associated Hyperkalemia: Effect of Laboratory Monitoring
    Marsha Raebel; Fiscal Year: 2007
    ..The findings will also assist in developing a framework for future studies to evaluate the effects and costs of medication-laboratory monitoring among patients with diabetes. [unreadable] [unreadable] [unreadable] [unreadable]..
  10. PREVENTION OF STROKE DYSFUNCTION BY ACE INHIBITION
    CHARLES STIER; Fiscal Year: 2001
    ..abstract_text> ..
  11. Genetic determinants of aldosterone escape in heart failure
    Larisa Cavallari; Fiscal Year: 2008
    ..goal of this line of investigation is to determine whether genotype is predictive of response to aldosterone antagonists in heart failure...
  12. Diabetes and Drug-Associated Hyperkalemia: Effect of Laboratory Monitoring
    Marsha Raebel; Fiscal Year: 2008
    ..The findings will also assist in developing a framework for future studies to evaluate the effects and costs of medication-laboratory monitoring among patients with diabetes. [unreadable] [unreadable] [unreadable] [unreadable]..
  13. PREVENTION OF STROKE DYSFUNCTION BY ACE INHIBITION
    CHARLES STIER; Fiscal Year: 2002
    ..abstract_text> ..
  14. PREVENTION OF STROKE DYSFUNCTION BY ACE INHIBITION
    CHARLES STIER; Fiscal Year: 2003
    ..abstract_text> ..
  15. HEART FAILURE & NORMAL SYSTOLIC FUNCTION IN OLDER ADULTS
    Frederick Masoudi; Fiscal Year: 2004
    ..abstract_text> ..
  16. ACTION - A CHF Trial Investigating Outcomes of Exercise
    Gregg Fonarow; Fiscal Year: 2006
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  17. PREVENTION OF STROKE DYSFUNCTION BY ACE INHIBITION
    CHARLES STIER; Fiscal Year: 2001
    ..abstract_text> ..
  18. PREVENTION OF STROKE & KIDNEY DYSFUNCTION
    CHARLES STIER; Fiscal Year: 1991
    ..Stroke is currently the nation's third largest killer (over 150,000 Americans/year). Our studies will provide important information in an area relevant to the therapy of hypertension, kidney dysfunction and stroke...
  19. PREVENTION OF STROKE DYSFUNCTION BY ACE INHIBITION
    CHARLES STIER; Fiscal Year: 2000
    ..abstract_text> ..
  20. THROMBOXANE IN SEVERE HYPERTENSION
    CHARLES STIER; Fiscal Year: 1990
    ..Stroke is currently the nation's third largest killer (over 150,000 Americans/year). Our studies will provide important information in an area relevant to the therapy of hypertension, kidney dysfunction and stroke...
  21. PREVENTION OF STROKE DYSFUNCTION BY ACE INHIBITION
    CHARLES STIER; Fiscal Year: 1999
    ..abstract_text> ..
  22. Vanderbilt Environmental Health Science Scholars Program
    Nancy Brown; Fiscal Year: 2008
    ..3) Leverage the shared resources of the Vanderbilt-Meharry Alliance to increase the number of underrepresented minorities serving as Scholars and Mentors and leaders in environmental health sciences research. ..
  23. DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORS
    David Archer; Fiscal Year: 2006
    ..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..
  24. GENES AND FIBRINOLYTIC CAPACITY OF HUMAN ENDOTHELIUM
    Nancy Brown; Fiscal Year: 2006
    ..It is expected that these pharmacogenetic studies will yield critical new information and strategies for enhancing the favorable effect of the kallikrein-kinin system on fibrinolysis and the risk of thrombotic cardiovascular events. ..
  25. Pharmacogenetics of ACE inhibitor-associated angioedema
    Nancy Brown; Fiscal Year: 2009
    ..In this way, this pharmacogenetic approach will provide new insight into the pathogenesis and prevention of this rare, but life-threatening, side effect of ACE inhibitors. ..
  26. RAAS, Inflammation & Post-Operative Atrial Fibrillation
    Nancy Brown; Fiscal Year: 2006
    ..abstract_text> ..
  27. ACTION - A CHF Trial Investigating Outcomes of Exercise
    CHRISTOPHER O CONNOR; Fiscal Year: 2008
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  28. Vanderbilt Mentored Clinical Research Scholar Program
    Nancy Brown; Fiscal Year: 2005
    ..The VCRS program will train successful new clinical investigators who will serve as leaders role in the post-genomic era. ..
  29. GENES AND FIBRINOLYTIC CAPACITY OF HUMAN ENDOTHELIUM
    Nancy Brown; Fiscal Year: 2005
    ..It is expected that these pharmacogenetic studies will yield critical new information and strategies for enhancing the favorable effect of the kallikrein-kinin system on fibrinolysis and the risk of thrombotic cardiovascular events. ..
  30. Renin-angiotensin and fibrinolysis interaction in humans
    Nancy Brown; Fiscal Year: 2005
    ..It is anticipated that these studies will generate critical new information regarding the mechanisms through which the RAA and kallikrein-kinin systems regulate vascular fibrinolytic function. ..
  31. Improving Outcomes in Diabetic Nephropathy
    Robert Toto; Fiscal Year: 2004
    ..abstract_text> ..
  32. Pharmacogenetics of ACE inhibitor-associated angioedema
    NANCY JOAN BROWN; Fiscal Year: 2010
    ..Understanding how ACE inhibitors and DPPIV inhibitors interact will help physicians prescribe these medications safely and will influence the development of new medications to treat diabetes and high blood pressure. ..
  33. Contingency Management for Initiating Smoking Abstinence
    WILLIAM BARRY WHITE; Fiscal Year: 2010
    ..Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be additional outcomes. We expect that BP and HR will decrease more among CM than non-CM patients and reductions in smoking may mediate decreases in these indices. ..
  34. Regulation of human sebaceous glands by 13-cis retinoic acid
    Diane Thiboutot; Fiscal Year: 2009
    ..The findings of these studies not only have the potential to advance our understanding of retinoid action in acne, but can lead to advances in the understanding of these agents in cancer biology and in innate immunity as well. ..
  35. Renin-angiotensin and fibrinolysis interaction in humans
    Nancy Brown; Fiscal Year: 2009
    ..These studies promise to yield novel pharmacological strategies to decrease the prevalence of diabetes and mortality due to thrombotic cardiovascular events in the metabolic syndrome. ..
  36. Building Interdisciplinary Research Careers in Women's Health
    Nancy Brown; Fiscal Year: 2008
    ..The success of each element will be evaluated using structured tools and benchmarks. We strive to create a new generation of creative, successful leaders in scientific areas that will improve the health of women. ..
  37. Improving Outcomes in Diabetic Nephropathy
    Robert Toto; Fiscal Year: 2008
    ..PERFORMANCE SITE ========================================Section End=========================================== ..
  38. African American Study of Kidney Disease and Hypertensi*
    Robert Toto; Fiscal Year: 2007
    ..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
  39. Lipoproteins, HIV, and Antiretroviral Therapy in SMART
    Daniel Duprez; Fiscal Year: 2008
    ..This proposal will produce additional information that will enhance their disease-free survival rate. (End of Abstract) [unreadable] [unreadable] [unreadable]..
  40. Heart Failure Clinical Research Network - RCC
    CHRISTOPHER O CONNOR; Fiscal Year: 2008
    ..The successful accomplishment of these aims will be a significant contribution to both the Heart Failure Network and the overall care of patients with heart failure. (End of Abstract) ..
  41. Contingency Management for Initiating Smoking Abstinence
    William White; Fiscal Year: 2008
    ..Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be additional outcomes. We expect that BP and HR will decrease more among CM than non-CM patients and reductions in smoking may mediate decreases in these indices. ..
  42. MENTORING PROGRAM FOR CLINICAL RESEARCHERS IN NEPHROLOGY
    Robert Toto; Fiscal Year: 2008
    ....
  43. RAAS, Inflammation & Post-Operative Atrial Fibrillation
    Nancy Brown; Fiscal Year: 2008
    ..abstract_text> ..
  44. MENTORING PROGRAM FOR CLINICAL RESEARCHERS IN NEPHROLOGY
    Robert Toto; Fiscal Year: 2007
    ....
  45. Improving Outcomes in Diabetic Nephropathy
    Robert Toto; Fiscal Year: 2005
    ..abstract_text> ..
  46. Regulation of Lipid Metabolism in Human Sebaceous Glands
    Diane Thiboutot; Fiscal Year: 2005
    ..Data generated from the proposed experiments will advance our understanding of the mechanisms regulating sebum production and can lead to identification of potential additional therapeutic target sites in the treatment of acne. ..
  47. Improving Outcomes in Diabetic Nephropathy
    Robert Toto; Fiscal Year: 2003
    ....
  48. TRAINING CURRICULUM IN PATIENT ORIENTED RESEARCH
    Robert Toto; Fiscal Year: 2004
    ..The proposed program will provide young physicians and scientists with the skills needed to conduct clinical investigations and to compete for federal and non-federal research funding. ..
  49. GENES AND FIBRINOLYTIC CAPACITY OF HUMAN ENDOTHELIUM
    Nancy Brown; Fiscal Year: 2001
    ..This collaborative proposal provides a robust mechanism for highly focused translational research in the molecular genetics and biology of the role of the fibrinolytic system in arterial and cerebral thrombosis. ..
  50. DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORS
    David Archer; Fiscal Year: 2003
    ..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..
  51. GENES AND FIBRINOLYTIC CAPACITY OF HUMAN ENDOTHELIUM
    Nancy Brown; Fiscal Year: 2002
    ..This collaborative proposal provides a robust mechanism for highly focused translational research in the molecular genetics and biology of the role of the fibrinolytic system in arterial and cerebral thrombosis. ..
  52. Renin-angiotensin and fibrinolysis interaction in humans
    Nancy Brown; Fiscal Year: 2002
    ..It is anticipated that these studies will generate critical new information regarding the mechanisms through which the RAA and kallikrein-kinin systems regulate vascular fibrinolytic function. ..
  53. Renin-angiotensin and fibrinolysis interaction in humans
    Nancy Brown; Fiscal Year: 2004
    ..It is anticipated that these studies will generate critical new information regarding the mechanisms through which the RAA and kallikrein-kinin systems regulate vascular fibrinolytic function. ..
  54. DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORS
    David Archer; Fiscal Year: 2002
    ..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..
  55. Improving Outcomes in Diabetic Nephropathy
    Robert Toto; Fiscal Year: 2002
    ....
  56. GENES AND FIBRINOLYTIC CAPACITY OF HUMAN ENDOTHELIUM
    Nancy Brown; Fiscal Year: 2003
    ..It is expected that these pharmacogenetic studies will yield critical new information and strategies for enhancing the favorable effect of the kallikrein-kinin system on fibrinolysis and the risk of thrombotic cardiovascular events. ..
  57. Pharmacogenetics of ACE inhibitor-associated angioedema
    Nancy Brown; Fiscal Year: 2006
    ..In this way, this pharmacogenetic approach will provide new insight into the pathogenesis and prevention of this rare, but life-threatening, side effect of ACE inhibitors. ..
  58. Vanderbilt Mentored Clinical Research Scholar Program
    Nancy Brown; Fiscal Year: 2004
    ..The VCRS program will train successful new clinical investigators who will serve as leaders role in the post-genomic era. ..
  59. Human Cardiorenal Syndrome
    Horng Chen; Fiscal Year: 2009
    ..This research should aid in addressing this health challenge. ..
  60. Mineralocorticoid Receptors in Cardiovascular Biology
    IRIS JAFFE; Fiscal Year: 2008
    ..The studies may also lead to new targets for the therapy of vascular diseases. ..
  61. COLLABORATIVE R01-CARDIAC GRAFTS-FUNCTIONAL ANALYSES
    Robert Kloner; Fiscal Year: 2002
    ....
  62. Mechanisms of Oxidative Stress and Inflammation during Prolonged Fasting and Slee
    Rudy M Ortiz; Fiscal Year: 2010
    ....
  63. The Effect of Aldosterone on Cerebral Blood Vessels
    Anne Dorrance; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  64. Mesenchymal Stem Cells for Myocardial Infarction
    Robert Kloner; Fiscal Year: 2003
    ..abstract_text> ..
  65. COLLABORATIVE R01-CARDIAC GRAFTS-FUNCTIONAL ANALYSES
    Robert Kloner; Fiscal Year: 2001
    ....
  66. Neurohormonal Blockade and Outcomes in Diastolic Heart Failure
    Ali Ahmed; Fiscal Year: 2010
    ..angiotensin-converting enzyme inhibitors (or angiotensin receptor blockers), beta-blockers and aldosterone antagonists, in three propensity-matched populations of Organized Program to Initiate Life-Saving Treatment in ..
  67. The Role of Vascular MR-Regulated Genes in Vascular Function and Disease
    Iris Z Jaffe; Fiscal Year: 2010
    ..abstract_text> ..
  68. COLLABORATIVE R01-CARDIAC GRAFTS-FUNCTIONAL ANALYSES
    Robert Kloner; Fiscal Year: 1999
    ....
  69. Beta Cell Adaptation to Stress in Baboon Pancreas After Partial Pancreatectomy
    FRANCO BATTISTA FOLLI; Fiscal Year: 2010
    ....
  70. Mechanisms of Oxidative Stress and Inflammation during Prolonged Fasting and Slee
    Rudy M Ortiz; Fiscal Year: 2010
    ....
  71. Defining the Mechanisms of Menopause-Associated Sleep and Mood Disturbances
    Hadine Joffe; Fiscal Year: 2009
    ..This work has important public health relevance because it will inform the development of rational therapeutic strategies and lead to novel treatment paradigms for menopause- associated depression. ..
  72. Activation of androgen biosynthesis and drug metabolism by cytochrome b5
    Richard Auchus; Fiscal Year: 2009
    ..This knowledge will provide a novel approach for suppressing androgen production, by targeting the CYP17A1-b5 interaction. ..
  73. VOLTAGE GATED CARDIAC POTASSIUM CHANNELS
    Katherine Murray; Fiscal Year: 1999
    ....
  74. HUMAN CARDIAC NA+ CHANNELS--EFFECTS OF PHOSPHORYLATION
    Katherine Murray; Fiscal Year: 1999
    ....
  75. VOLTAGE GATED CARDIAC POTASSIUM CHANNELS
    Katherine Murray; Fiscal Year: 2000
    ....
  76. COLLABORATIVE R01-CARDIAC GRAFTS-FUNCTIONAL ANALYSES
    Robert Kloner; Fiscal Year: 2000
    ....
  77. HUMAN CARDIAC NA+ CHANNELS--EFFECTS OF PHOSPHORYLATION
    Katherine Murray; Fiscal Year: 2000
    ....
  78. Heart failure, chronic kidney disease, and renin-angiotensin system inhibition
    Ali Ahmed; Fiscal Year: 2009
    ....
  79. Oxidized Linoleic Acid, Aldosterone, and Obesity
    THEODORE GOODFRIEND; Fiscal Year: 2006
    ..abstract_text> ..
  80. A Molecular Target for Atrial Fibrillation
    Katherine Murray; Fiscal Year: 2006
    ..The knowledge gained from these studies will improve our understanding of the molecular components of atrial electrophysiology and facilitate the development of novel strategies in the treatment of atrial fibrillation. ..
  81. A Molecular Target for Atrial Fibrillation
    Katherine Murray; Fiscal Year: 2004
    ..The knowledge gained from these studies will improve our understanding of the molecular components of atrial electrophysiology and facilitate the development of novel strategies in the treatment of atrial fibrillation. ..
  82. The Effect of Aldosterone on Cerebral Blood Vessels
    Anne Dorrance; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  83. G6PD AND OXIDANT STRESS IN VASCULAR SMOOTH MUSCLE CELLS
    Jane Leopold; Fiscal Year: 2004
    ..abstract_text> ..
  84. Heart failure, chronic kidney disease, and renin-angiotensin system inhibition
    Ali Ahmed; Fiscal Year: 2006
    ....
  85. Molecular Modulation of Cardiac Na+ Channel Function
    Katherine Murray; Fiscal Year: 2004
    ..abstract_text> ..
  86. Fusion Proteins As Probes of P450 Structure and Function
    Richard Auchus; Fiscal Year: 2004
    ..In addition, this approach might be generally applicable to structural studies of membrane-bound proteins. ..
  87. MICROVASC OBSTRUCTION BY MRI AFTER CORONARY INTERVENTION
    Katherine Wu; Fiscal Year: 2004
    ..abstract_text> ..
  88. Oxidized Linoleic Acid, Aldosterone, and Obesity
    THEODORE GOODFRIEND; Fiscal Year: 2007
    ..abstract_text> ..
  89. Mesenchymal Stem Cells for Myocardial Infarction
    Robert Kloner; Fiscal Year: 2004
    ..abstract_text> ..
  90. Aldosterone in angiotensin II-induced hypertension
    Rudy Ortiz; Fiscal Year: 2005
    ..Unlike previous studies, the present study will provide a more comprehensive examination of the renal effects induced by aldo antagonism. ..
  91. The Effect of Aldosterone on Cerebral Blood Vessels
    Anne Dorrance; Fiscal Year: 2005
    ..These studies will elucidate a novel role for aldosterone in the pathogenesis of cerebrovascular disease, they will show that aldosterone not only increases EGFR density but also acts as a signaling molecule to enhance EGFR activation. ..
  92. Mesenchymal Stem Cells for Myocardial Infarction
    Robert Kloner; Fiscal Year: 2005
    ..abstract_text> ..
  93. A Molecular Target for Atrial Fibrillation
    Katherine Murray; Fiscal Year: 2005
    ..The knowledge gained from these studies will improve our understanding of the molecular components of atrial electrophysiology and facilitate the development of novel strategies in the treatment of atrial fibrillation. ..